HeartBeam Study Shows Comparable Accuracy to Standard ECG in Arrhythmia Detection
HeartBeam's 3D ECG system demonstrates comparable accuracy to standard 12-lead ECGs in detecting arrhythmias, potentially expanding advanced cardiac monitoring to non-clinical settings.
HeartBeam (NASDAQ: BEAT) announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter, and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, demonstrated high accuracy rates in both groups, with 94.5% for HeartBeam compared to 95.5% for standard 12-lead ECG.
The findings highlight the potential of HeartBeam's compact, 3D device to expand advanced cardiac monitoring to settings where full 12-lead ECGs may be impractical. CEO Rob Eno emphasized that this technology could redefine cardiac health management by enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities. The company plans to use these results to support future FDA submissions for its 12-lead ECG synthesis software, which is currently under FDA review.
HeartBeam's technology represents a significant advancement in portable cardiac monitoring, creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and it holds over 20 issued patents related to technology enablement. This development could potentially transform how cardiac conditions are detected and monitored, making advanced cardiac care more accessible in various settings beyond traditional medical facilities.
The study results validate the company's approach to delivering actionable heart intelligence through portable devices that can be used wherever the patient is located. For more details on the company's technology and regulatory status, visit https://ibn.fm/BDiIa. The implications of this technology extend beyond clinical accuracy to potentially reducing healthcare costs and improving patient outcomes through earlier detection and monitoring of cardiac conditions in non-hospital environments.